- Clinical bacteriology
- Molecular diagnostics
- Epidemiology of bacterial infections
- Clostridium difficile
Department of Medical Microbiology
Professor of Experimental Bacteriology, MD
PI Epidemiology, diagnosis and treatment of Clostridium difficile infections
- Recognition of bacterial virulence markers available for therapeutic interventions
- New typing methods for studying the epidemiology of hospital-acquired bacterial diaseases, yeasts and fungi
- Application and implementation of new-generation mass-spectrometry in clinical microbiology to recognise multidrug resistance
- The role of the microbiota in infectious diseases
Prof. Dr. E.J. Kuijper (medical microbiologist) has been working at the Department of Medical Microbiology at the LUMC since 2000 and is currently the head of the Department of Experimental Microbiology and the National Reference Laboratory for Clostridium difficile. He is (co)author of more than 220 articles published in peer reviewed journals and books and participated in more than 300 abstracts for national and international scientific meetings. During the past 15 years, he obtained several grants to study meningococcal infections, complement deficiencies, atypical mycobacterial infections, fungal infections, and gastro-intestinal infections. Already in 1987, he was interested in Clostridium difficile and developed a molecular typing method (restriction fragment length polymorphism) which is still regarded as the standard typing method in USA. In 2000, the first large epidemic of a toxin A-negative C. difficile in the Netherlands was detected. This large epidemic due to an new, probably more virulent strain, resulted in research focusing on optimalization of diagnostics and typing of C. difficile infections, and studies to toxin genes and its regulation. Recent outbreaks of the emerging C. difficile hypervirulent variants 027 and 078 in the Netherlands and other European countries resulted in an intensive collaboration with experts from abroad in combined research projects, such as EACCAD (FP6) and Hyperdiff (FP7). In 2005, the National Reference Laboratory for Clostridium difficile was set up in the LUMC in close collaboration with the National Institute of Public Health (Centre for Infectious Disease Control) in Bilthoven. Since 2008, Dr. E.J. Kuijper is president of the European Study Group on Clostridum difficile (ESCGD), which has been co-opted by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Dr. Kuijper has also been affiliated with the European Centre for Disease Prevention and Control to coordinate European activities of C. difficile and is currently leading a project to support European capacity building of CDI.
Debast SB, Bauer MP, Kuijper EJ; Committee. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014; 20 Suppl 2:1-26.
Knetsch CW, Lawley TD, Hensgens MP, Corver J, Wilcox MW, Kuijper EJ. Current application and future perspectives of molecular typing methods to study Clostridium difficile infections. Euro Surveill 2013; 18:20381.
Hensgens MP, Goorhuis A, Dekkers OM, van Benthem BH, Kuijper EJ. All-Cause and Disease-Specific Mortality in Hospitalized Patients With Clostridium difficile Infection: A Multicenter Cohort Study. Clin Infect Dis 2013; 56:1108-16.
van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-15.
Bauer MP, Hensgens MP, Miller MA, Gerding DN, Wilcox MH, Dale AP, Fawley WN, Kuijper EJ, Gorbach SL. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. Clin Infect Dis 2012; 55 Suppl 2:S149-53.
Hensgens MP, Keessen EC, Squire MM, Riley TV, Koene MG, de Boer E, Lipman LJ, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases Study Group for Clostridium difficile (ESGCD). Clostridium difficile infection in the community: a zoonotic disease? Clin Microbiol Infect 2012; 18:635-45.
Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. J Infect 2013; 66:115-28.
Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012; 67:742-8.
Koene MG, Mevius D, Wagenaar JA, Harmanus C, Hensgens MP, Meetsma AM, Putirulan FF, van Bergen MA, Kuijper EJ. Clostridium difficile in Dutch animals: their presence, characteristics and similarities with human isolates. Clin Microbiol Infect 2012; 18:778-84.
Goorhuis A, Debast SB, Dutilh JC, van Kinschot CM, Harmanus C, Cannegieter SC, Hagen EC, Kuijper EJ. Type-specific risk factors and outcome in an outbreak with 2 different Clostridium difficile types simultaneously in 1 hospital. Clin Infect Dis 2011; 53:860-9.
Hensgens MP, Goorhuis A, van Kinschot CM, Crobach MJ, Harmanus C, Kuijper EJ. Clostridium difficile infection in an endemic setting in the Netherlands. Eur J Clin Microbiol Infect Dis 2011; 30:587-93.
Leids Universitair Medisch Centrum
2333 ZA Leiden
Tel: +31 (0)715263574
2300 RC Leiden